HRT vs Peptides Side Effects: What You Need to Know

Side effects are the part of the conversation that every patient deserves honesty about. Too often, people receive either a dismissive “it’s very safe” with no real detail, or a fear-based presentation of risks that ignores context, dose, and the significant evolution in how these therapies are administered.

Both HRT and peptide therapy have side effect profiles and both profiles are more nuanced than headlines suggest. The risks of HRT are frequently overstated based on a 2002 study that used oral synthetic hormones at high doses in older women, and the findings do not translate neatly to modern bioidentical, transdermal approaches in appropriately selected patients. The risks of peptide therapy are often understated because the field is newer and many people are accessing compounds without proper clinical guidance.

My goal in this post is to give you the complete, honest picture not to sell you on either approach, but to help you understand what you are considering so you can make an informed decision in partnership with a qualified provider.

At 1st Optimal, we believe that informed patients make better decisions and have better outcomes. This is that information.

Table of Contents

How Risk Should Be Understood in Context

Before diving into specific side effects, I want to establish a framework for thinking about risk that is grounded in reality rather than anxiety or overconfidence.

All medical interventions carry risk. So does inaction. The meaningful question is never “does this carry any risk?” but rather “what is the magnitude of the risk, for whom, and how does it compare to the benefit and to the alternatives?”

Several factors shape the risk profile of any hormonal or peptide therapy:

The specific compound and formulation. Oral synthetic estrogen carries different risks than transdermal bioidentical estradiol. Compounding pharmacy quality affects peptide safety. These are not interchangeable.

The dose. Most side effects are dose-dependent. Appropriate dosing within physiological ranges carries very different risk than supraphysiological or excessive dosing.

The individual’s health history. A woman with no personal or family history of breast cancer and no clotting disorders faces a different risk calculus than someone with those factors. Personalization matters.

The quality of oversight. Appropriate monitoring catches problems early and allows course correction. Therapy without monitoring carries higher risk than well-monitored therapy.

Duration. Some risks are cumulative over time; others are acute. Understanding whether a risk is primarily short-term or long-term shapes how it should be weighed.

With this framework in place, let me walk through the specific side effect profiles.

Side Effects of Estrogen Therapy in Women

Estrogen therapy carries several commonly cited risks that deserve honest examination.

Breast Cancer This is the risk most often raised by patients, and it deserves careful context. The 2002 WHI study found an increased breast cancer risk associated with combined estrogen plus synthetic progestin therapy. However, estrogen-only therapy (in women without a uterus) did not show the same increased risk and was actually associated with reduced breast cancer incidence in the WHI data.

The type of progestogen matters significantly. Synthetic progestins such as medroxyprogesterone acetate used in the original WHI study appear to carry different risk than micronized bioidentical progesterone. Observational studies from France and other European settings have found that estrogen combined with bioidentical progesterone does not carry the same breast cancer signal as synthetic progestin combinations.

For appropriately selected women using transdermal estradiol with micronized progesterone, the evidence suggests a more favorable risk profile than older data would suggest. This does not mean zero risk, it means the risk is context-dependent and may be much lower than the headline number most women have heard.

Blood Clots and Stroke Oral estrogen increases clotting risk due to first-pass liver metabolism that affects clotting factors. Transdermal estradiol, which bypasses the liver, has a significantly lower, and potentially neutral, risk of venous thromboembolism compared to oral estrogen. For women at elevated clotting risk, this distinction in delivery method is clinically significant.

Endometrial Cancer Estrogen without progesterone can stimulate the uterine lining and increase endometrial cancer risk. This is why progesterone is always co-prescribed for women with a uterus. With appropriate progesterone, this risk is effectively neutralized.

Common Short-Term Side Effects

Breast tenderness or swelling (often resolves with dose adjustment)
Bloating or water retention
Nausea (more common with oral forms)
Headaches (particularly in women with migraine history)
Mood fluctuations during initiation or dose changes

Side Effects of Progesterone Therapy

Progesterone is the hormone with the most favorable side effect profile in the HRT spectrum, particularly when used in its bioidentical form (micronized progesterone) rather than as synthetic progestins.

Micronized Progesterone This form available as oral or topical preparations has a profile that most patients tolerate well. The primary effect worth noting is sedation: progesterone has mild sedating properties mediated through GABA-A receptor activity. Many women actually appreciate this effect, as taking micronized progesterone at bedtime often improves sleep quality.

Other potential effects include:

Mild breast tenderness
Mild bloating or water retention at higher doses
Rare mood changes (though progesterone generally has a positive effect on mood and anxiety)

Synthetic Progestins (Not Recommended in Modern Protocols) Older synthetic progestins like medroxyprogesterone acetate (MPA) have a significantly less favorable side effect profile, including mood disturbance, bloating, depression, and the breast cancer risk signal identified in the WHI. At 1st Optimal, we do not use synthetic progestins, we use bioidentical progesterone.

The important takeaway: if you have been prescribed a synthetic progestin and are experiencing significant side effects, the first conversation to have with your provider is whether switching to bioidentical micronized progesterone is appropriate for you.

Side Effects of Testosterone Therapy in Women

I covered this in Post 16, but a summary belongs here for completeness.

Testosterone therapy in women, when dosed to maintain physiologically appropriate levels, has a favorable safety profile. Side effects are primarily related to excess dosing:

Acne
Increased facial or body hair
Oily skin
Scalp hair thinning
Clitoral enlargement (at very high doses)
Voice changes (at very high doses largely irreversible, making appropriate dosing critical)

These effects are dose-dependent and generally preventable with careful titration and monitoring. The Global Consensus Position Statement on testosterone use in women concluded that physiologically dosed testosterone has an acceptable safety profile.

The most clinically important point: working with a provider who doses conservatively and monitors appropriately is the primary strategy for avoiding these effects.

Side Effects of Testosterone Therapy in Men

Testosterone therapy in men has a more complex side effect profile due to higher physiological doses and the broader range of conditions being treated.

Erythrocytosis (Elevated Red Blood Cell Count) Testosterone stimulates red blood cell production. When hematocrit rises above approximately 54 percent, blood viscosity increases in a way that elevates cardiovascular risk. This is monitored regularly and managed by dose adjustment or therapeutic phlebotomy if needed. It is one of the primary reasons regular monitoring is essential.

Testicular Atrophy and Fertility Exogenous testosterone suppresses the body’s own testosterone production via the hypothalamic-pituitary axis, leading to testicular atrophy and significant reduction in sperm production. For men who wish to preserve fertility, this is a critical consideration. Co-treatment with agents that preserve pituitary function is available and should be discussed with a provider.

Cardiovascular Risk The cardiovascular effects of testosterone therapy in men have been debated extensively. The landmark TRAVERSE trial, published in 2023, found that testosterone therapy did not significantly increase major cardiovascular events in men with documented hypogonadism and elevated cardiovascular risk, a finding that meaningfully clarified the risk landscape. However, men with existing significant cardiovascular disease require careful individual evaluation.

Estrogen Conversion (Aromatization) Testosterone converts to estradiol through aromatization. In men, some estradiol is necessary for bone health, libido, and cardiovascular function. However, excess conversion can cause symptoms such as gynecomastia (breast tissue development), water retention, and mood changes. Monitoring estradiol and adjusting dosing or using aromatase management when indicated is standard in well-run testosterone therapy programs.

Other Common Side Effects

Fluid retention, particularly early in therapy
Acne, particularly in younger men or at higher doses
Sleep apnea (may be exacerbated by testosterone therapy)
Prostate volume increase (benign; requires monitoring of PSA)

Side Effects of Peptide Therapy

Peptide therapy has a generally favorable safety profile compared to traditional HRT, particularly because most clinical peptides stimulate the body’s own processes rather than directly introducing hormones. However, side effects do exist and deserve honest discussion.

Growth Hormone-Releasing Peptides This category is the most widely used in clinical wellness settings. Potential side effects include:

Water retention: One of the most common effects, particularly early in therapy or with higher doses. Manifests as puffiness or bloating. Generally resolves with dose adjustment.
Carpal tunnel symptoms: Fluid retention can cause transient nerve compression symptoms in the wrist. Usually resolves with dose reduction.
Increased appetite: GH release stimulates appetite. Most patients find this manageable; those managing weight may need to account for it.
Fatigue or drowsiness: Can occur with certain peptides in this class, typically when doses are taken at times other than before sleep.
Hypoglycemia: Some GH-releasing peptides can transiently lower blood glucose. Particularly relevant for people with diabetes or insulin sensitivity. Monitoring glucose is important in these individuals.
IGF-1 elevation: IGF-1 is a downstream marker of GH activity. Sustained supraphysiological IGF-1 levels have theoretical cancer-promoting associations based on epidemiological data. Monitoring IGF-1 and keeping it within an appropriate range is a standard part of responsible peptide therapy.

Tissue Repair Peptides Side effects in this class are generally mild and include nausea at higher doses and occasional injection site reactions. Serious adverse events are uncommon in the published literature, though long-term human clinical trial data is more limited for this category.

Injection Site Reactions Any peptide administered subcutaneously may cause local reactions including redness, mild swelling, or bruising at the injection site. These are generally mild and transient.

Theoretical Concerns Around Cancer Because GH and IGF-1 are growth-promoting factors, concern has been raised about whether therapies that raise these levels could theoretically promote cancer growth. It is important to note that the evidence for this concern comes primarily from epidemiological associations with naturally high IGF-1 levels — not from clinical trials of peptide therapy in appropriate populations. Nonetheless, individuals with active cancer or a personal history of certain cancers should discuss this carefully with their oncologist before considering GH-pathway peptide therapy.

Comparing the Risk Profiles — Key Differences

When comparing the side effect profiles of HRT and peptide therapy, several meaningful differences emerge.

Hormonal Directness HRT directly introduces exogenous hormones, which carry specific risks tied to those hormones’ biological effects. Peptide therapy, particularly GH-releasing peptides works through the body’s own signaling systems, which creates a different and generally more self-limiting risk profile.

Long-Term Evidence HRT has decades of clinical data behind it, including large-scale randomized controlled trials. The risk picture is well characterized, and the field has refined its understanding significantly since the 2002 WHI data. Peptide therapy has a smaller evidence base, particularly for long-term effects beyond two to three years in most compound categories.

Reversibility Peptide therapy is generally more easily reversible than HRT. If you stop a peptide protocol, the compound clears the system relatively quickly and the body returns to its baseline state. Stopping HRT involves its own transition and the return of whatever symptoms the therapy was managing.

Monitoring Requirements Both approaches require appropriate monitoring, but the specific markers differ. HRT monitoring focuses on hormone levels, hematocrit (for testosterone users), and cancer screening. Peptide monitoring focuses on IGF-1, glucose, and symptom assessment.

Individual Variability Both approaches require individualization. “Average” risk data does not predict individual experience. This is why thorough clinical evaluation is essential for both.

Minimizing Risks — The Role of Monitoring

The most consistent theme across every category of side effect I have described is that appropriate monitoring dramatically reduces the likelihood of experiencing significant adverse effects, and enables early detection when issues arise.

At 1st Optimal, our monitoring approach includes:

Before Starting Any Protocol

Comprehensive baseline labs covering hormones, metabolic markers, and cancer screening markers
Full health history review including personal and family cancer history
Review of current medications for potential interactions
Cardiovascular risk assessment for individuals on or considering testosterone therapy

During Therapy

Hormone level checks at four to six weeks and three months initially
IGF-1 monitoring for peptide therapy patients
Hematocrit monitoring for testosterone therapy patients
PSA monitoring for men on testosterone therapy
Regular symptom review to detect emerging concerns early

Ongoing

Semi-annual or annual comprehensive labs depending on protocol and individual stability
Annual physical examination with appropriate cancer screening per age and risk guidelines
Dose adjustments based on labs and symptom evolution

The goal is not surveillance for its own sake, it is ensuring that the protocol continues to deliver benefit without accumulating risk over time.

The Risk of Doing Nothing

I want to close the main content of this post with a point that is often omitted from discussions of HRT and peptide therapy side effects: the risk of leaving hormonal deficiency and physiological aging untreated is not zero.

Unmanaged estrogen deficiency in women is associated with accelerated bone loss and elevated fracture risk, increased cardiovascular risk, vaginal atrophy, cognitive decline, and significantly reduced quality of life. The WHI’s own long-term follow-up data found that women in the estrogen-therapy arm had lower all-cause mortality over the follow-up period compared to those on placebo [6].

Unmanaged testosterone deficiency in men is associated with increased mortality, reduced bone density, metabolic syndrome, depression, and reduced quality of life. The TRAVERSE trial data reinforced that managed testosterone therapy does not meaningfully increase cardiac risk in hypogonadal men.

Declining growth hormone activity with age contributes to unfavorable body composition, poor sleep, reduced tissue repair capacity, and accelerated biological aging. These are not trivial quality-of-life concerns, they are physiologically meaningful changes with downstream health consequences.

The decision about whether to treat is not a choice between risk and no risk. It is a choice between two different risk profiles, the risks of treatment versus the risks of untreated decline. That decision, made thoughtfully with good data and a qualified provider, is yours to make.

FAQs:

Is HRT dangerous? The risks of HRT are real but context-dependent. Modern bioidentical, transdermal HRT in appropriately selected patients carries a significantly different risk profile than the oral synthetic formulations studied in the 2002 WHI trial. For many women, the benefits of properly managed HRT substantially outweigh the risks. The decision requires individualized evaluation, not blanket generalizations.
Are peptides safer than HRT? For most applications, peptide therapy has a favorable safety profile. Because most clinical peptides work through the body’s own signaling systems rather than introducing exogenous hormones, some of the risks specific to HRT are not present. However, peptides are not without their own considerations, and the smaller evidence base means some long-term risks are less characterized.
What is the most serious risk of HRT? The most discussed serious risk is breast cancer in women on combined estrogen-progestin therapy. However, this risk appears significantly lower with bioidentical progesterone versus synthetic progestins, and lower still with transdermal versus oral estrogen. Estrogen-only therapy in women without a uterus has not demonstrated a breast cancer risk increase in the WHI data.
Can peptides cause cancer? No direct evidence from clinical trials demonstrates that appropriately dosed clinical peptide therapy causes cancer. Theoretical concern exists based on the growth-promoting properties of GH and IGF-1, and individuals with active cancer or high cancer risk should discuss this with specialists before starting GH-pathway peptide therapy. IGF-1 monitoring is standard in well-run peptide programs.
What are the most common side effects of testosterone therapy? In women: acne, mild hirsutism, and oily skin at doses that are too high. In men: erythrocytosis (elevated red blood cell count), fluid retention, and acne. All are manageable with appropriate dosing and monitoring.
Will I gain weight on HRT? HRT itself is not associated with weight gain, in fact, estrogen and testosterone therapy are associated with more favorable body composition in appropriate candidates. Some patients experience initial fluid retention during the first few weeks, which typically resolves. Overall, well-managed HRT tends to support body composition rather than undermine it.
What happens if I get a side effect from HRT or peptides? In most cases, side effects are dose-related and respond to dose adjustment. Your provider should be accessible to discuss emerging concerns and modify your protocol accordingly. This is why working with a provider who actively monitors your progress rather than just prescribing and disappearing is important.
Are bioidentical hormones safer than synthetic hormones? There is meaningful evidence that bioidentical progesterone has a more favorable safety profile than synthetic progestins, particularly regarding breast cancer risk. Transdermal bioidentical estradiol has a more favorable clotting risk profile than oral synthetic estrogen. The term “bioidentical” has also been misused in direct-to-consumer marketing to imply blanket safety, which is not accurate dosing, monitoring, and appropriateness for the individual still matter.
How long can I safely stay on HRT or peptide therapy? There is no universal time limit supported by current evidence. For women who are symptomatic and benefiting from HRT, current major medical society guidelines do not recommend arbitrary discontinuation at a specific age or after a specific duration. The decision to continue or discontinue should be based on ongoing risk-benefit review with your provider. For peptide therapy, long-term safety data beyond several years is more limited, and the conversation should be ongoing.
Do I need to stop HRT before surgery? Oral estrogen is typically discontinued two to four weeks before major elective surgery due to clotting risk. Transdermal estradiol carries much lower clotting risk and stopping may not be necessary, this should be determined by your surgeon and prescribing provider working together. This is another reason the delivery method of your HRT matters.
Can men use HRT without affecting fertility? Standard testosterone therapy suppresses sperm production and is not appropriate for men planning biological children in the near future. Fertility-preserving approaches are available and should be discussed with a specialist before starting therapy.
What should I do if I have a family history of breast cancer? A family history of breast cancer does not automatically disqualify someone from HRT, but it requires a more careful individual risk-benefit evaluation ideally in consultation with a breast health specialist or oncologist familiar with hormonal therapies. At 1st Optimal, we take family history seriously and incorporate it into our clinical decision-making.

Conclusion

Side effects are a real part of any medical conversation, and they deserve honesty rather than minimization or exaggeration. The truth about HRT and peptide therapy is that both have real but manageable risk profiles profiles that look very different depending on the specific compounds used, how they are dosed, and how well the therapy is monitored.

The patients who do best are the ones who understand their risk profile going in, work with a provider who takes monitoring seriously, and stay engaged with their own health data as therapy progresses. Fear of side effects should not be a reason to leave a hormone deficiency or physiological decline unaddressed. But that same fear, channeled into asking good questions and demanding good oversight, is exactly what leads to safe, effective outcomes.

At 1st Optimal, we never dismiss your concerns about side effects, we take them as an opportunity to explain, educate, and design a protocol that balances what you are hoping to gain with the safest possible approach to getting there.